

Supplementary Information

Directed nucleophilic aromatic substitution reaction

Yasuyuki Nitta, Yusei Nakashima, Mchinori Sumimoto, Takashi Nishikata**

*Graduate School of Science and Engineering, Yamaguchi University 2-16-1 Tokiwadai,
Ube, Yamaguchi, 755-8611, Japan*

Table of Contents


1. General Information	S2
2. Optimization of Reaction Conditions	S3
3. General Procedures	S11
4. Spectral Charts for Products	S39

1. General Information

All reactions were carried out under nitrogen (99.95%) atmosphere. For TLC analyses precoated Kieselgel 60 F254 plates (Merck, 0.25 mm thick) were used; for column chromatography Silica Flash® P60 (SiliCycle, 40-63 μm) was used. Visualization was accomplished by UV light (254 nm), ^1H , ^{13}C , and ^{19}F NMR spectra were obtained using a JEOL 500 MHz NMR spectrometer. Chemical shifts for ^1H NMR were described in parts per million (chloroform as an internal standard $\delta = 7.26$) in CDCl_3 , unless otherwise noted. Chemical shifts for ^{13}C NMR were expressed in parts per million in CDCl_3 as an internal standard ($\delta = 77.16$), unless otherwise noted. High resolution mass analyses (HRMS) were obtained using an ACQUITY UPLC/TOF-MS for ESI. Infrared spectra were recorded on Agilent Technologies Cary 630 FTIR. Anhydrous solvents were purchased from Kanto Chemical Co., Ltd. Other chemicals were purchased from TCI, Aldrich, and Wako and directly used without further purification. UV-visible absorption spectra were recorded on a JASCO V-750 spectrometer. Fluorescence spectra were recorded on a JASCO FP-8250 fluorescence spectrometer.

2. Optimization and Comparison of Reaction Conditions


Table S1. Optimization



entry	deviation from the standard conditions	NMR yield (%)
1	none	49
2	5.0 equiv. of amine	>99
3	Pyridine instead of Pyridine·HCl	14
4	Trimethylamine·HCl instead of Pyridine·HCl	18
5	Piperidine·HCl instead of Pyridine·HCl	19
6	DMAP instead of Pyridine·HCl	trace
7	AcOH instead of Pyridine·HCl	10
8	CSA instead of Pyridine·HCl	23
9	Pyridine + CSA instead of Pyridine·HCl	55 ^a
10	CsF instead of Cs ₂ CO ₃	trace
11	Et ₃ N instead of Cs ₂ CO ₃	0
12	MeOH as solvent	31
13	MeCN as solvent	30
14	<i>conditions B</i>	>99


Reaction yields were determined by ¹H NMR using 1,1,2,2-Tetrachloroethane as an internal standard. DMAP: 4-Dimethylaminopyridine, CSA: (±)-10-Camphorsulfonic Acid
^aAdd Pyridine (5 mol%) and CSA (5 mol%). *conditions B*: 1a (1.0 equiv.), 2a (5.0 equiv.), K₃PO₄ (2.0 equiv.), CsOAc (1.0 equiv.), Pyridine (1.0 M), 80°C, 24 h

Table S2. Screening of catalysts (conditions A)




^aUsed as solvent (0.25 M) and w/o catalyst. ^bUsed 5.0 equiv. of amine.

Table S3. Screening of solvents (anhydrous) (conditions A)




Entry	solvent	NMR yield
1	DCM	49%
2	MeOH	31%
3	MeCN	30%
4	Acetone	trace
5	THF	trace

Table S4. Screening of bases (conditions A)




Entry	base	NMR yield
1	Cs ₂ CO ₃	49%
2	Na ₂ CO ₃	0%
3	K ₂ CO ₃	0%
4	Li ₂ CO ₃	0%
5	CsF	trace
6	CsOAc	0%
7	Et ₃ N	0%
8	DBU	0%
9	DABCO	trace

Table S5. Screening of equivalent of amine (conditions A)



Entry	xx equiv.	NMR yield
1	5.0	>99%
2	3.0	49%
3	2.0	16%
4	1.0	trace

Table S6. Screening of equivalent of base (conditions A)



Entry	xx equiv.	NMR yield
1	3.0	>99%
2	2.0	76%
3	1.0	62%

Table S7. Screening of directing groups (conditions A)






Table S8. Screening of bases (conditions B)



Entry	base	NMR yield
1	CsF	9%(7% ^a)
2	K ₃ PO ₄	5%(5% ^a)
3	DBU	15%
4	Cs ₂ CO ₃	0%
5	Li ₂ CO ₃	0%
6	Na ₂ CO ₃	0%
7	K ₂ CO ₃	0%
8	CsOAc	0%
9	NaOAc	0%
10	KOAc	0%
11	NaO ^t Bu	0%
12	KO ^t Bu	0%
13	DABCO	0%
14	Et ₃ N	0%
15	DIPA	0%
16	DIPEA	0%
17	w/o base	0%

^aisolated yield

Table S9. Screening of solvent (conditions B)



Solvent	NMR yield		
	CsF	K ₃ PO ₄	DBU
DCM	9%(7% ^a)	5%(5% ^a)	15%
DCE	0%	1%	4%
Chloroform	2%	2%	8%
Acetonitrile	1%	0%	3%
Diethyl ether	5%	2%	5%
AcOEt	0%	1%	5%
Pyridine ^b	2%	2%	2%
Pyridine ^c	18%	11%	16%
Pyridine ^d	1%	0%	9%
Pyridine ^e	2%	2%	6%
Pyridine ^f	17%	51%(40% ^a)	18%

^aisolated yield. ^bw/o Catalyst. ^cadded CSA (5 mol%) instead of a catalyst. ^dadded CSA (1.0 equiv.) instead of a catalyst. ^eadded CSA (20 mol%) instead of a catalyst. ^fadded CSA (5 mol%) instead of a catalyst and 80°C.


Table S10. Screening of various conditions (conditions B)

Entry	deviation from the standard conditions	NMR yield
1	none	51%
2	50°C instead of 80°C	12%
3	Pyridine/H ₂ O = 95:5 (1.0 M)	62%
4	add CsOAc (1.0 equiv.) and Pyridine/H ₂ O = 95:5 (1.0 M)	74%
5	add Cs ₂ CO ₃ (1.0 equiv.) and Pyridine/H ₂ O = 95:5 (1.0 M)	62%
6	add CsF (1.0 equiv.) and Pyridine/H ₂ O = 95:5 (1.0 M)	7%
7	K ₃ PO ₄ (1.0 equiv.), CsOAc (1.0 equiv.) and Pyridine/H ₂ O = 95:5 (1.0 M)	60%
8	K ₃ PO ₄ (2.0 equiv.), CsOAc (1.0 equiv.) and Pyridine/H ₂ O = 95:5 (1.0 M)	75%
9	K ₃ PO ₄ (2.0 equiv.), CsOAc (0.5 equiv.), and Pyridine/H ₂ O = 95:5 (1.0 M)	63%
10	K ₃ PO ₄ (2.0 equiv.), CsOAc (0.8 equiv.), and Pyridine/H ₂ O = 95:5 (1.0 M)	68%
11	K ₃ PO ₄ (2.0 equiv.), CsOAc (1.0 equiv.), Pyridine/H ₂ O = 95:5 (1.0 M) and 24 h	81%
12	w/o CSA, K ₃ PO ₄ (2.0 equiv.), CsOAc (1.0 equiv.), Pyridine/H ₂ O = 95:5 (1.0 M) and 24 h	79%
13	w/o CSA, K ₃ PO ₄ (2.0 equiv.), CsOAc (1.0 equiv.), Pyridine (1.0 M) and 24 h	>99%

Table S11. Screening of equivalent of amine (conditions B)

2a (equiv.)	NMR yield of 3a	2b (equiv.)	NMR yield of 3b
2.0	>99%	2.0	38%
5.0	>99%	5.0	>99%


Table S11. Regio-isomers study under various conditions



3. General procedures


General procedure for the synthesis of 3, 4 and 6

Condition A;




An oven-dried 5.0 mL screw-cap vial equipped with magnetic stir bar was charged with corresponding aromatic halides **1** (0.5 mmol, 1.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.), Amines **2** (2.5 mmol, 5.0 equiv.), and Dichloromethane (0.5~2.0 mL) were added in a nitrogen-filled glovebox. The reaction mixture was stirred at room temperature for 20 h. After this time, the reaction mixture was filtered through the plug of silica gel, and then concentrated by rotary evaporation. Yield was determined by ¹H NMR analysis using 1,1,2,2-tetrachloroethane as an internal standard. After the mixture was concentrated by evaporation, the residue was purified by flash chromatography, eluting hexane/EtOAc to afford the product.

Condition B;




An oven-dried 5.0 mL screw-cap vial equipped with magnetic stir bar was charged with corresponding aromatic halides **1** (0.5 mmol, 1.0 equiv.), K₃PO₄ (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.), Amines **2** (2.5 mmol, 5.0 equiv.), and Pyridine (0.5 mL) were added in a nitrogen-filled glovebox. The reaction mixture was stirred at 80°C for 24 h. After this time, the reaction mixture was filtered through the plug of silica gel, and then concentrated by rotary evaporation. Yield was determined by ¹H NMR analysis using 1,1,2,2-tetrachloroethane as an internal standard. After the mixture was concentrated by evaporation, the residue was purified by flash chromatography, eluting hexane/EtOAc to afford the product.

Condition C;




An oven-dried 5.0 mL screw-cap vial equipped with magnetic stir bar was charged with corresponding aromatic halides **1** (0.5 mmol, 1.0 equiv.), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.), Amines **2** (2.5 mmol, 5.0 equiv.), and Pyridine (1.0 mL) were added in a nitrogen-filled glovebox. The reaction mixture was stirred at room temperature for 20 h. After this time, the reaction mixture was filtered through the plug of silica gel, and then concentrated by rotary evaporation. Yield was determined by ¹H NMR analysis using 1,1,2,2-tetrachloroethane as an internal standard. After the mixture was concentrated by evaporation, the residue was purified by flash chromatography, eluting hexane/EtOAc to afford the product.

2-(butylamino)-N-phenylbenzamide (**3a**)



Following the general procedure above (Condition A), using **1a** (161.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (2.0 mL) at room temperature for 20 h, yielded the product **3a** (133.5 mg, 99%), Viscous colorless oil.; IR (neat) ν 3391, 3286, 2958, 2931, 2868, 1633, 748, 691 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.95 (t, J = 7.4 Hz, 3H), 1.45 (sext, J = 7.4 Hz, 2H), 1.66 (quint, J = 7.3 Hz, 2H), 3.16 (t, J = 7.1 Hz, 2H), 6.62 (t, J = 7.5 Hz, 1H), 6.73 (d, J = 8.1 Hz, 1H), 7.15 (t, J = 7.4 Hz, 1H), 7.33-7.39 (m, 3H), 7.41 (brs, 1H), 7.49 (dd, J = 1.5 Hz and 7.9 Hz, 1H), 7.54 (d, J = 8.3 Hz, 2H), 7.72 (brs, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.4, 42.9, 112.0, 114.6, 114.9, 120.8, 124.5, 127.5, 129.2, 133.4, 138.0, 150.3, 168.3; HRMS (TOF-MS) calcd. for C₁₇H₂₁N₂O (M+H⁺): 269.1654; found 269.1653


N-phenyl-2-(p-tolylamino)benzamide (**3b**)



Following the general procedure above (Condition B), using **1a** (161.6 mg, 0.50 mmol), **2b** (267.9 mg, 2.5 mmol, 5.0 equiv.), K₃PO₄ (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **3b** (123.3 mg, 82%), Viscous colorless oil.; IR (neat) ν 3380, 3344, 2915, 1637, 1594, 1506, 1430, 1316, 805 cm⁻¹; ¹H NMR (CDCl₃)


δ : 2.32 (s, 3H), 6.78-6.81 (m, 1H), 7.09-7.13 (m, 4H), 7.16 (t, $J = 7.3$ Hz, 1H), 7.27-7.31 (m, 2H), 7.38 (t, $J = 7.8$ Hz, 2H), 7.57 (d, $J = 7.8$ Hz, 3H), 7.87 (brs, 1H), 9.07 (brs, 1H). ^{13}C NMR (CDCl_3) δ : 21.0, 115.5, 117.7, 118.0, 120.8, 122.0, 124.8, 127.6, 129.3, 130.0, 132.8, 132.9, 137.8, 138.6, 146.8, 168.0.; HRMS (TOF-MS) calcd. for $\text{C}_{20}\text{H}_{19}\text{N}_2\text{O}$ ($\text{M}+\text{H}^+$): 303.1497; found 303.1497

2-((3-ethoxypropyl)amino)-N-phenylbenzamide (**3c**)




Following the general procedure above (Condition A), using **1a** (161.6 mg, 0.50 mmol), **2c** (0.30 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs_2CO_3 (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **3c** (135.8 mg, 91%), Viscous colorless oil.; IR (neat) ν 2971, 1637, 1578, 1357, 1152, 1022 cm^{-1} ; ^1H NMR (CDCl_3) δ : 1.26 (t, $J = 7.0$ Hz, 3H), 1.93 (quint, $J = 6.4$ Hz, 2H), 3.28 (q, $J = 4.3$ Hz, 2H), 3.48 (q, $J = 7.0$ Hz, 2H), 3.54 (t, $J = 6.1$ Hz, 2H), 6.64 (t, $J = 7.6$ Hz, 1H), 6.77 (d, $J = 8.2$ Hz, 1H), 7.14 (t, $J = 7.4$ Hz, 1H), 7.32-7.38 (m, 3H), 7.43 (brs, 1H), 7.48 (d, $J = 7.8$ Hz, 1H), 7.54 (d, $J = 8.1$ Hz, 2H), 7.74 (brs, 1H). ^{13}C NMR (CDCl_3) δ : 15.3, 29.6, 40.4, 66.4, 68.3, 112.1, 114.8, 115.2, 120.7, 124.5, 127.6, 129.2, 133.4, 138.0, 150.1, 168.3.; HRMS (TOF-MS) calcd. for $\text{C}_{18}\text{H}_{23}\text{N}_2\text{O}_2$ ($\text{M}+\text{H}^+$): 299.1760; found 299.1761

2-((3-isopropoxypropyl)amino)-N-phenylbenzamide (**3d**)




Following the general procedure above (Condition A), using **1a** (161.6 mg, 0.50 mmol), **2d** (0.35 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs_2CO_3 (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **3d** (154.1 mg, 98%), Viscous colorless oil.; IR (neat) ν 3388, 3296, 2974, 2935, 2861, 1637, 1428, 1296, 1098, 746 cm^{-1} ; ^1H NMR (CDCl_3) δ : 1.15 (d, $J = 6.2$ Hz, 6H), 1.90 (quint, $J = 6.3$ Hz, 2H), 3.28 (t, $J = 6.6$ Hz, 2H), 3.52-3.59 (m, 3H), 6.64 (t, $J = 7.3$ Hz, 1H), 6.78 (d, $J = 8.5$ Hz, 1H), 7.14 (t, $J = 7.4$ Hz, 1H), 7.32-7.38 (m, 3H), 7.42 (brs, 1H), 7.48 (d, $J = 7.9$ Hz, 1H), 7.54 (d, $J = 8.3$ Hz, 2H), 7.76 (brs, 1H). ^{13}C NMR (CDCl_3) δ : 22.2, 29.9, 40.4, 65.8, 71.7, 112.1, 114.8, 115.2, 120.7, 124.5, 127.6, 129.2, 133.4, 138.0, 150.2, 168.2.; HRMS (TOF-MS) calcd. for $\text{C}_{19}\text{H}_{25}\text{N}_2\text{O}_2$ ($\text{M}+\text{H}^+$): 313.1916; found 313.1916

2-((2,2-diethoxyethyl)amino)-*N*-phenylbenzamide (**3e**)




Following the general procedure above (Condition A), using **1a** (161.6 mg, 0.50 mmol), **2e** (0.36 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, ¹H NMR yielded the product **3e** (97%), Viscous colorless oil.; IR (neat) ν 3373, 3311, 2975, 2926, 2893, 1636, 1541, 1063, 750 cm⁻¹; ¹H NMR (CDCl₃) δ : 1.24 (t, *J* = 7.1 Hz, 6H), 3.34 (t, *J* = 5.6 Hz, 2H), 3.56-3.62 (m, 2H), 3.71-3.77 (m, 2H), 4.71 (t, *J* = 5.6 Hz, 1H), 6.67 (t, *J* = 7.8 Hz, 1H), 6.78 (d, *J* = 8.4 Hz, 1H), 7.14 (t, *J* = 7.4 Hz, 1H), 7.32-7.38 (m, 3H), 7.46 (brs, 1H), 7.49 (d, *J* = 7.8 Hz, 1H), 7.58 (d, *J* = 7.6 Hz, 2H), 7.78 (brs, 1H). ¹³C NMR (CDCl₃) δ : 15.5, 46.2, 62.6, 101.2, 112.4, 115.4, 116.2, 120.5, 124.5, 127.6, 129.2, 133.3, 138.1, 149.7, 167.9.; HRMS (TOF-MS) calcd. for C₁₉H₂₅N₂O₃ (M+H⁺): 329.1865; found 329.1864

2-(allylamino)-*N*-phenylbenzamide (**3f**)




Following the general procedure above (Condition A), using **1a** (161.6 mg, 0.50 mmol), **2f** (0.19 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **3f** (121.9 mg, 97%), Viscous colorless oil.; IR (neat) ν 3395, 3264, 2832, 1738, 1633, 1578, 1514, 1231, 749 cm⁻¹; ¹H NMR (CDCl₃) δ : 3.84 (d, *J* = 4.4 Hz, 2H), 5.17 (d, *J* = 10.2 Hz, 1H), 5.30 (d, *J* = 17.5 Hz, 1H), 5.90-5.80 (m, 1H), 6.65 (t, *J* = 8.0 Hz, 1H), 6.71 (d, *J* = 8.0 Hz, 1H), 7.15 (t, *J* = 7.5 Hz, 1H), 7.32-7.39 (m, 3H), 7.50 (d, *J* = 7.7 Hz, 1H), 7.56 (d, *J* = 8.2 Hz, 2H), 7.61 (brs, 1H), 7.78 (brs, 1H). ¹³C NMR (CDCl₃) δ : 45.6, 112.4, 115.1, 115.4, 116.3, 120.7, 124.6, 127.5, 129.2, 133.3, 134.8, 138.0, 149.9, 168.3.; HRMS (TOF-MS) calcd. for C₁₆H₁₇N₂O (M+H⁺): 253.1341; found 253.1341

2-((2-(dimethylamino)ethyl)amino)-N-phenylbenzamide (**3g**)




Following the general procedure above (Condition A), using **1a** (161.6 mg, 0.50 mmol), **2g** (0.27 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (2.0 mL) at room temperature for 20 h, yielded the product **3g** (136.3 mg, 96%), Viscous colorless oil.; IR (neat) ν 3313, 2944, 2818, 2772, 1630, 1595, 1515, 1219, 742 cm⁻¹; ¹H NMR (CDCl₃) δ : 2.28 (s, 6H), 2.58 (t, J = 6.7 Hz, 2H), 3.27 (q, J = 5.4 Hz, 2H), 6.65 (t, J = 7.3 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 7.13 (t, J = 7.4 Hz, 1H), 7.33-7.37 (m, 4H), 7.50 (d, J = 7.9 Hz, 1H), 7.55 (d, J = 7.9 Hz, 2H), 7.87 (brs, 1H). ¹³C NMR (CDCl₃) δ : 41.1, 45.5, 58.1, 112.2, 115.3, 116.0, 120.7, 124.5, 127.8, 129.2, 133.4, 138.1, 149.7, 168.1.; HRMS (TOF-MS) calcd. for C₁₇H₂₂N₃O (M+H⁺): 284.1763; found 284.1764

2-((2-morpholinoethyl)amino)-N-phenylbenzamide (**3h**)




Following the general procedure above (Condition A), using **1a** (161.6 mg, 0.50 mmol), **2h** (0.33 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **3h** (147.2 mg, 90%), Viscous colorless oil.; IR (neat) ν 3301, 3240, 2918, 2805, 1656, 1592, 1482, 1260, 1105, 746 cm⁻¹; ¹H NMR (CDCl₃) δ : 2.48 (s, 4H), 2.64 (t, J = 6.2 Hz, 2H), 3.26 (q, J = 6.2 Hz, 2H), 3.71 (t, J = 4.5 Hz, 4H), 6.71 (t, J = 7.3 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 7.12 (t, J = 7.3 Hz, 1H), 7.32-7.36 (m, 3H), 7.46-7.49 (m, 2H), 7.55 (d, J = 7.9 Hz, 2H), 7.84 (brs, 1H). ¹³C NMR (CDCl₃) δ : 40.2, 53.7, 57.3, 67.1, 112.1, 115.2, 116.1, 120.6, 124.5, 127.7, 129.2, 133.3, 138.1, 149.7, 168.0.; HRMS (TOF-MS) calcd. for C₁₉H₂₄N₃O₂ (M+H⁺): 326.1869; found 326.1870

N-phenyl-2-((pyridin-2-ylmethyl)amino)benzamide (**3i**)




Following the general procedure above (Condition A), using **1a** (161.6 mg, 0.50 mmol), **2i** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **3i** (153.0 mg, 99%), Viscous colorless oil.; IR (neat) ν 3337, 3258, 3052, 1633, 1514, 1438, 1228, 747 cm⁻¹; ¹H NMR (CDCl₃) δ : 4.58 (d, J = 5.9 Hz, 2H), 6.65 (d, J = 8.5 Hz, 1H), 6.68 (t, J = 7.8 Hz, 1H), 7.14-7.18 (m, 2H), 7.26-7.29 (m, 1H), 7.36-7.40 (m, 3H), 7.53 (d, J = 7.8 Hz, 1H), 7.58-7.64 (m, 3H), 7.90 (brs, 1H), 8.12 (brs, 1H), 8.59 (d, J = 4.9 Hz, 1H). ¹³C NMR (CDCl₃) δ : 49.1, 112.8, 115.7, 116.0, 120.7, 121.2, 122.0, 124.7, 127.6, 129.2, 133.4, 137.0, 138.0, 149.5, 149.6, 159.1, 168.2.; HRMS (TOF-MS) calcd. for C₁₉H₁₈N₃O (M+H⁺): 304.1450; found 304.1451

N-phenyl-2-(((tetrahydrofuran-2-yl)methyl)amino)benzamide (**3j**)



Following the general procedure above (Condition A), using **1a** (161.6 mg, 0.50 mmol), **2j** (0.26 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **3j** (147.7 mg, 99%), Viscous colorless oil.; IR (neat) ν 3383, 3290, 2862, 1739, 1634, 1515, 1425, 1235, 1072, 744 cm⁻¹; ¹H NMR (CDCl₃) δ : 1.65-1.72 (m, 1H), 1.85-1.99 (m, 2H), 2.02-2.09 (m, 1H), 3.26 (d, J = 5.8 Hz, 2H), 3.78 (q, J = 7.0 Hz, 1H), 3.92 (q, J = 6.6 Hz, 1H), 4.15 (quint, J = 6.1 Hz, 1H), 6.65 (t, J = 7.6 Hz, 1H), 6.77 (d, J = 8.3 Hz, 1H), 7.14 (t, J = 7.3 Hz, 1H), 7.32-7.37 (m, 3H), 7.49 (d, J = 7.8 Hz, 1H), 7.53 (brs, 1H), 7.56 (d, J = 7.7 Hz, 2H), 7.81 (brs, 1H). ¹³C NMR (CDCl₃) δ : 25.9, 29.6, 47.7, 68.4, 77.5, 112.3, 115.2, 115.8, 120.7, 124.5, 127.6, 129.2, 133.3, 138.1, 150.1, 168.1.; HRMS (TOF-MS) calcd. for C₁₈H₂₁N₂O₂ (M+H⁺): 297.1603; found 297.1605


2-(((furan-2-yl)methyl)amino)-N-phenylbenzamide (**3k**)



Following the general procedure above (Condition B), using **1a** (161.6 mg, 0.50 mmol), **2k** (0.23 mL, 2.5 mmol, 5.0 equiv.), K₃PO₄ (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **3k** (137.9 mg, 94%), Viscous colorless oil.; IR (neat) ν 3377, 3331, 3053, 2924, 2850, 1636, 1576, 1503, 1441, 1144 cm⁻¹; ¹H NMR (CDCl₃) δ : 4.38 (s, 2H), 6.25 (d, J = 3.2 Hz, 1H), 6.30-6.31 (m, 1H), 6.69 (t, J = 7.5 Hz, 1H), 6.80 (d,


$J = 8.3$ Hz, 1H), 7.15 (t, $J = 7.5$ Hz, 1H), 7.33-7.38 (m, 4H), 7.50 (d, $J = 8.1$ Hz, 1H), 7.55 (d, $J = 8.3$ Hz, 2H), 7.79 (brs, 2H). ^{13}C NMR (CDCl_3) δ : 40.6, 107.1, 110.4, 112.3, 115.7, 116.0, 120.8, 124.7, 127.5, 129.2, 133.4, 137.9, 142.1, 149.5, 152.4, 168.1.; HRMS (TOF-MS) calcd. for $\text{C}_{18}\text{H}_{17}\text{N}_2\text{O}_2$ ($\text{M}+\text{H}^+$): 293.1290; found 293.1292

2-(benzylamino)-N-phenylbenzamide (**3l**)



Following the general procedure above (Condition A), using **1a** (161.6 mg, 0.50 mmol), **2l** (0.27 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs_2CO_3 (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **3l** (79.2 mg, 52%), Viscous colorless oil.; IR (neat) ν 3421, 3232, 3065, 3026, 1592, 1494, 1426, 1231, 746 cm^{-1} ; ^1H NMR (CDCl_3) δ : 4.42 (d, $J = 5.6$ Hz, 2H), 6.64-6.68 (m, 2H), 7.15 (t, $J = 7.4$ Hz, 1H), 7.23-7.39 (m, 8H), 7.50 (d, $J = 7.7$ Hz, 1H), 7.55 (d, $J = 8.5$ Hz, 2H), 7.76 (brs, 1H), 7.94 (brs, 1H). ^{13}C NMR (CDCl_3) δ : 47.3, 112.6, 115.3, 115.5, 120.8, 124.7, 127.2, 127.3, 127.4, 128.8, 129.2, 133.4, 137.9, 139.0, 149.9, 168.3.; HRMS (TOF-MS) calcd. for $\text{C}_{20}\text{H}_{19}\text{N}_2\text{O}$ ($\text{M}+\text{H}^+$): 303.1497; found 303.1499


N-phenyl-2-((3-phenylpropyl)amino)benzamide (**3m**)



Following the general procedure above (Condition A), using **1a** (161.6 mg, 0.50 mmol), **2m** (0.36 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs_2CO_3 (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **3m** (125.5 mg, 76%), Viscous colorless oil.; IR (neat) ν 3389, 3344, 3023, 2926, 2852, 1637, 1577, 1509, 742 cm^{-1} ; ^1H NMR (CDCl_3) δ : 2.01 (quint, $J = 7.6$ Hz, 2H), 2.76 (t, $J = 7.6$ Hz, 2H), 3.18 (t, $J = 5.5$ Hz, 2H), 6.64 (t, $J = 7.3$ Hz, 1H), 6.68 (d, $J = 8.5$ Hz, 1H), 7.15 (t, $J = 7.4$ Hz, 1H), 7.19-7.21 (m, 3H), 7.28 (t, $J = 7.7$ Hz, 2H), 7.33 (t, $J = 7.4$ Hz, 1H), 7.38 (t, $J = 7.8$ Hz, 2H), 7.49 (d, $J = 8.1$ Hz, 1H), 7.52 (brs, 1H), 7.55 (d, $J = 8.5$ Hz, 2H), 7.72 (brs, 1H). ^{13}C NMR (CDCl_3) δ : 30.7, 33.4, 42.4, 112.0, 114.8, 115.0, 120.8, 124.6, 126.0, 127.5, 128.5, 128.6, 129.2, 133.4, 138.0, 141.7, 150.2,


168.3.; HRMS (TOF-MS) calcd. for C₂₂H₂₃N₂O (M+H⁺): 331.1810; found 331.1813

2-(neopentylamino)-N-phenylbenzamide (**3n**)




Following the general procedure above (Condition B), using **1a** (161.6 mg, 0.50 mmol), **2n** (0.29 mL, 2.5 mmol, 5.0 equiv.), K₃PO₄ (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **3n** (124.5 mg, 88%), Viscous colorless oil.; IR (neat) ν 3383, 3301, 2952, 1736, 1631, 1517, 1228, 752 cm⁻¹; ¹H NMR (CDCl₃) δ : 1.04 (s, 9H), 2.95 (d, *J* = 5.0 Hz, 2H), 6.60 (t, *J* = 7.6 Hz, 1H), 6.75 (d, *J* = 8.1 Hz, 1H), 7.14 (t, *J* = 7.4 Hz, 1H), 7.33 (t, *J* = 8.1 Hz, 1H), 7.37 (t, *J* = 7.7 Hz, 2H), 7.48 (d, *J* = 7.7 Hz, 1H), 7.55 (d, *J* = 8.5 Hz, 2H), 7.69 (brs, 1H), 7.73 (brs, 1H). ¹³C NMR (CDCl₃) δ : 27.9, 32.0, 55.2, 112.0, 114.4, 114.7, 120.8, 124.5, 127.6, 129.2, 133.4, 138.1, 151.0, 168.4.; HRMS (TOF-MS) calcd. for C₁₈H₂₃N₂O (M+H⁺): 283.1810; found 283.1811

2-(sec-butylamino)-N-phenylbenzamide (**3o**)




Following the general procedure above (Condition B), using **1a** (161.6 mg, 0.50 mmol), **2o** (0.25 mL, 2.5 mmol, 5.0 equiv.), K₃PO₄ (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **3o** (91.2 mg, 68%), Viscous colorless oil.; IR (neat) ν 3365, 3272, 3068, 2960, 2927, 2873, 1632, 1578, 1513, 1443, 1245, 1164, 741 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.97 (t, *J* = 7.3 Hz, 3H), 1.21 (d, *J* = 6.2 Hz, 3H), 1.49-1.56 (m, 1H), 1.60-1.69 (m, 1H), 3.45-3.50 (m, 1H), 6.59 (t, *J* = 7.5 Hz, 1H), 6.73 (d, *J* = 8.5 Hz, 1H), 7.14 (t, *J* = 7.2 Hz, 1H), 7.32 (t, *J* = 7.5 Hz, 1H), 7.37 (t, *J* = 7.7 Hz, 2H), 7.40 (brs, 1H), 7.48 (d, *J* = 8.0 Hz, 1H), 7.53 (d, *J* = 8.5 Hz, 2H), 7.75 (brs, 1H). ¹³C NMR (CDCl₃) δ : 10.6, 20.2, 29.6, 49.3, 112.5, 114.3, 114.8, 120.8, 124.5, 127.8, 129.2, 133.4, 138.0, 149.7, 168.4.; HRMS (TOF-MS) calcd. for C₁₇H₂₁N₂O (M+H⁺): 269.1654; found 269.1656

2-(cyclohexylamino)-N-phenylbenzamide (**3p**)




Following the general procedure above (Condition B), using **1a** (161.6 mg, 0.50 mmol), **2p** (0.29 mL, 2.5 mmol, 5.0 equiv.), K_3PO_4 (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **3p** (124.8 mg, 85%), Viscous colorless oil.; IR (neat) ν 3339, 3307, 2922, 2849, 1641, 1499, 1422, 1250, 744 cm^{-1} ; 1H NMR ($CDCl_3$) δ : 1.24-1.41 (m, 5H), 1.61-1.65 (m, 1H), 1.76-1.78 (m, 2H), 2.02-2.05 (m, 2H), 3.35 (brs, 1H), 6.59 (t, $J = 7.4$ Hz, 1H), 6.75 (d, $J = 8.4$ Hz, 1H), 7.14 (t, $J = 7.4$ Hz, 1H), 7.31 (t, $J = 7.9$ Hz, 1H), 7.37 (t, $J = 8.2$ Hz, 2H), 7.43 (brs, 1H), 7.48 (d, $J = 7.9$ Hz, 1H), 7.53 (d, $J = 7.9$ Hz, 2H), 7.76 (brs, 1H). ^{13}C NMR ($CDCl_3$) δ : 25.0, 26.1, 33.0, 51.0, 112.6, 114.4, 114.8, 120.8, 124.5, 127.8, 129.2, 133.3, 138.0, 149.3, 168.3.; HRMS (TOF-MS) calcd. for $C_{19}H_{23}N_2O$ ($M+H^+$): 295.1810; found 295.1811

2-((4-methoxyphenyl)amino)-N-phenylbenzamide (**3q**)




Following the general procedure above (Condition B), using **1a** (161.6 mg, 0.50 mmol), **2q** (307.9 mg, 2.5 mmol, 5.0 equiv.), K_3PO_4 (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **3q** (74.5 mg, 47%), Viscous colorless oil.; IR (neat) ν 3249, 3126, 2952, 2833, 1626, 1586, 1507, 1446, 1239, 1031, 743 cm^{-1} ; 1H NMR ($CDCl_3$) δ : 3.81 (s, 3H), 6.75 (t, $J = 7.5$ Hz, 1H), 6.89 (d, $J = 9.0$ Hz, 2H), 7.10 (d, $J = 8.3$ Hz, 1H), 7.13-7.18 (m, 3H), 7.27 (t, $J = 9.0$ Hz, 1H), 7.38 (t, $J = 8.0$ Hz, 2H), 7.55 (d, $J = 8.0$ Hz, 1H), 7.58 (d, $J = 8.5$ Hz, 2H), 7.85 (brs, 1H), 9.04 (brs, 1H). ^{13}C NMR ($CDCl_3$) δ : 55.6, 114.8, 116.9, 117.1, 120.8, 124.80, 124.84, 127.5, 129.3, 133.0, 134.1, 137.9, 148.0, 156.3, 168.1.; HRMS (TOF-MS) calcd. for $C_{20}H_{18}N_2NaO_2$ ($M+H^+$): 341.1266; found 341.1266

2-((4-bromophenyl)amino)-N-phenylbenzamide (**3r**)




Following the general procedure above (Condition B), using **1a** (161.6 mg, 0.50 mmol), **2r** (430.1 mg, 2.5 mmol, 5.0 equiv.), K_3PO_4 (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **3r** (123.9 mg, 68%), Viscous colorless oil.; IR (neat) ν 3348, 1739, 1637, 1583, 1509, 1433, 1317, 1254, 808 cm^{-1} ; 1H NMR ($CDCl_3$) δ : 6.84-6.89 (m, 1H), 7.06 (d, $J = 8.7$ Hz, 2H), 7.17 (t, $J = 7.3$ Hz, 1H), 7.33 (d, $J = 3.8$ Hz, 2H), 7.37-7.40 (m, 4H), 7.55-7.59 (m, 3H), 7.88 (brs, 1H), 9.17 (brs, 1H). ^{13}C NMR ($CDCl_3$) δ : 114.8, 116.0, 118.8, 119.1, 120.9, 122.3, 125.0, 127.7, 129.3, 132.4, 132.9, 137.6, 140.6, 145.3, 167.8.; HRMS (TOF-MS) calcd. for $C_{19}H_{16}BrN_2O$ ($M+H^+$): 367.0446; found 367.0448

N-phenyl-2-(pyrrolidin-1-yl)benzamide (**3s**)




Following the general procedure above (Condition B), using **1a** (161.6 mg, 0.50 mmol), **2s** (0.21 mL, 2.5 mmol, 5.0 equiv.), K_3PO_4 (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, 1H NMR yielded the product **3s** (75%), Viscous colorless oil.; IR (neat) ν 3307, 2958, 2848, 1737, 1645, 1597, 1523, 1490, 1438, 1321, 1237, 752 cm^{-1} ; 1H NMR ($CDCl_3$) δ : 1.99-2.04 (m, 4H), 3.21-3.24 (m, 4H), 7.09-7.15 (m, 3H), 7.36 (t, $J = 7.6$ Hz, 2H), 7.41 (t, $J = 7.8$ Hz, 1H), 7.66 (d, $J = 7.8$ Hz, 2H), 8.01 (d, $J = 7.8$ Hz, 1H), 10.8 (brs, 1H). ^{13}C NMR ($CDCl_3$) δ : 24.9, 52.7, 118.5, 119.7, 122.4, 123.9, 126.9, 129.2, 131.1, 132.0, 138.9, 148.1, 165.9.; HRMS (TOF-MS) calcd. for $C_{17}H_{19}N_2O$ ($M+H^+$): 267.1497; found 267.1498

2-amino-N-phenylbenzamide (**3t**)




Following the general procedure above (Condition B), using **1a** (161.6 mg, 0.50 mmol), **2t** (3.0 mL), K_3PO_4 (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **3t** (74.5 mg, 70%), Viscous colorless oil.; IR (neat) ν 3466, 3359, 3273, 3035, 1597, 1534, 1438, 1249, 1151, 746 cm^{-1} ; 1H NMR ($CDCl_3$) δ : 5.47 (brs, 2H), 6.67-6.70 (m, 2H), 7.13 (t, $J = 7.4$ Hz, 1H), 7.22-7.25 (m, 1H), 7.35 (t, $J = 7.7$ Hz, 2H), 7.45 (d, $J = 8.3$ Hz, 1H), 7.54 (d, $J = 8.5$ Hz, 2H), 7.82 (brs, 1H). ^{13}C NMR ($CDCl_3$) δ : 116.3, 116.9, 117.6, 120.7, 124.6, 127.3, 129.1, 132.8, 137.9, 149.0, 167.7.; HRMS (TOF-MS) calcd. for $C_{13}H_{13}N_2O$ ($M+H^+$): 213.1028; found 213.1029

2-(butylamino)-3-methyl-N-phenylbenzamide (**4b**)



Following the general procedure above (Condition B), using **1b** (168.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), K_3PO_4 (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **4b** (139.6 mg, 99%), Viscous colorless oil.; IR (neat) ν 3308, 2956, 2927, 2860, 1648, 1594, 1540, 1438, 1315, 1250, 750 cm^{-1} ; 1H NMR ($CDCl_3$) δ : 0.88 (t, $J = 7.3$ Hz, 3H), 1.36 (sext, $J = 7.3$ Hz, 2H), 1.60 (quint, $J = 7.7$ Hz, 2H), 2.35 (s, 3H), 2.99 (t, $J = 7.3$ Hz, 2H), 3.67 (brs, 1H), 7.07 (t, $J = 7.6$ Hz, 1H), 7.12 (t, $J = 7.5$ Hz, 1H), 7.30 (d, $J = 7.4$ Hz, 1H), 7.36 (t, $J = 7.5$ Hz, 2H), 7.70 (d, $J = 7.6$ Hz, 2H), 7.94 (d, $J = 7.9$ Hz, 1H), 11.02 (brs, 1H). ^{13}C NMR ($CDCl_3$) δ : 14.0, 18.0, 20.4, 32.9, 51.1, 120.0, 123.3, 123.9, 127.2, 129.1, 129.5, 130.6, 133.9, 138.9, 145.8, 165.6; HRMS (TOF-MS) calcd. for $C_{18}H_{23}N_2O$ ($M+H^+$): 283.1810; found 283.1811


2-(butylamino)-5-methyl-N-phenylbenzamide (**4c**)



Following the general procedure above (Condition A), using **1c** (168.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs_2CO_3 (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **4c** (100.1 mg, 71%), Viscous colorless oil.; IR (neat) ν 3391, 3274, 2929, 2866, 1638, 1519, 1426, 748 cm^{-1} ; 1H NMR ($CDCl_3$) δ : 0.94 (t, $J = 7.4$ Hz, 3H), 1.45 (sext, $J = 7.4$ Hz, 2H), 1.64 (quint, $J = 7.1$ Hz, 2H), 2.28 (s, 3H), 3.14 (t, $J = 7.2$ Hz, 2H), 6.67 (d, $J = 8.6$ Hz, 1H), 7.12-7.18 (m, 3H), 7.29 (s, 1H),


7.37 (t, $J = 7.7$ Hz, 2H), 7.55 (d, $J = 8.4$ Hz, 2H), 7.76 (brs, 1H). ^{13}C NMR (CDCl_3) δ : 14.0, 20.4, 20.5, 31.5, 43.2, 112.3, 115.1, 120.7, 123.8, 124.5, 127.7, 129.2, 134.2, 138.1, 148.2, 168.2; HRMS (TOF-MS) calcd. for $\text{C}_{18}\text{H}_{23}\text{N}_2\text{O}$ ($\text{M}+\text{H}^+$): 283.1810; found 283.1809

2-(butylamino)-4,5-dimethoxy-N-phenylbenzamide (**4d**)




Following the general procedure above (Condition B), using **1d** (191.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), K_3PO_4 (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **4d** (149.4 mg, 91%), Viscous colorless oil.; IR (neat) ν 3353, 2929, 2862, 1631, 1508, 1425, 1201, 1165, 756 cm^{-1} ; ^1H NMR (CDCl_3) δ : 0.95 (t, $J = 7.4$, 3H), 1.45 (sext, $J = 7.6$, 2H), 1.66 (quint, $J = 7.3$, 2H), 3.14 (t, $J = 7.1$, 2H), 3.84 (s, 3H), 3.89 (s, 3H), 6.25 (brs, 1 H), 7.09 (brs, 1H), 7.12 (t, $J = 7.3$, 1H), 7.34 (t, $J = 7.5$, 2H), 7.53 (d, $J = 7.9$, 2H), 7.97 (brs, 1H). ^{13}C NMR (CDCl_3) δ : 14.0, 20.5, 31.5, 44.0, 55.8, 57.6, 96.4, 106.4, 112.5, 120.9, 124.3, 129.1, 138.2, 139.7, 147.1, 154.5, 167.7; HRMS (TOF-MS) calcd. for $\text{C}_{19}\text{H}_{25}\text{N}_2\text{O}_3$ ($\text{M}+\text{H}^+$): 329.1865; found 329.1867

N-butyl-2-(butylamino)benzamide (**4e**)




Following the general procedure above (Condition B), using **1e** (151.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), K_3PO_4 (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **4e** (114.5 mg, 92%), Viscous colorless oil.; IR (neat) ν 3332, 2956, 2928, 2861, 1626, 1514, 1273, 1161, 742 cm^{-1} ; ^1H NMR (CDCl_3) δ : 0.93 (t, $J = 7.3$ Hz, 3H), 0.94 (t, $J = 7.3$ Hz, 3H), 1.35-1.48 (m, 4H), 1.56 (quint, $J = 6.8$ Hz, 2H), 1.64 (quint, $J = 6.8$ Hz, 2H), 3.11 (t, $J = 7.0$ Hz, 2H), 3.37 (q, $J = 7.0$ Hz, 2H), 6.14 (brs, 1H), 6.52 (t, $J = 7.3$ Hz, 1H), 6.66 (d, $J = 8.3$ Hz, 1H), 7.25 (t, $J = 8.3$ Hz, 1H), 7.30 (dd, $J = 1.5$ and 7.8 Hz, 1H), 7.49 (brs, 1H). ^{13}C NMR (CDCl_3) δ : 13.9, 14.0, 20.3, 20.5, 31.4, 31.8, 39.5, 42.9, 111.6, 114.3, 115.3, 127.3, 132.7, 149.9, 170.0; HRMS (TOF-MS) calcd. for $\text{C}_{15}\text{H}_{25}\text{N}_2\text{O}$ ($\text{M}+\text{H}^+$): 249.1967; found 249.1967

N-benzyl-2-(butylamino)benzamide (**4f**)




Following the general procedure above (Condition B), using **1f** (168.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), K_3PO_4 (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **4f** (139.8 mg, 99%), Viscous colorless oil.; IR (neat) ν 3340, 3033, 2953, 2927, 2849, 1627, 1509, 1452, 1275, 1158 cm^{-1} ; 1H NMR ($CDCl_3$) δ : 0.97 (t, $J = 7.0$ Hz, 3H), 1.47 (sext, $J = 7.6$ Hz, 2H), 1.67 (quint, $J = 7.3$ Hz, 2H), 3.15 (t, $J = 6.7$ Hz, 2H), 4.60 (d, $J = 5.6$ Hz, 2H), 6.33 (brs, 1H), 6.54 (t, $J = 7.9$ Hz, 1H), 6.70 (d, $J = 8.4$ Hz, 1H), 7.28-7.38 (m, 7H), 7.61 (brs, 1H). ^{13}C NMR ($CDCl_3$) δ : 14.0, 20.5, 31.4, 42.9, 43.8, 111.9, 114.5, 114.6, 127.4, 127.6, 127.9, 128.9, 133.0, 138.4, 150.0, 169.8; HRMS (TOF-MS) calcd. for $C_{18}H_{23}N_2O$ ($M+H^+$): 283.1810; found 283.1807

2-(butylamino)-N-(2,6-dimethylphenyl)benzamide (**4g**)




Following the general procedure above (Condition A), using **1g** (175.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs_2CO_3 (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **4g** (145.2 mg, 98%), Viscous colorless oil.; IR (neat) ν 3255, 2956, 2924, 2856, 1628, 1509, 1234, 1275, 1234, 1159, 741 cm^{-1} ; 1H NMR ($CDCl_3$) δ : 0.94 (t, $J = 7.1$ Hz, 3H), 1.44 (sext, $J = 7.5$ Hz, 2H), 1.64 (quint, $J = 7.4$ Hz, 2H), 2.29 (s, 6H), 3.15 (t, $J = 6.9$ Hz, 2H), 6.64 (t, $J = 7.3$ Hz, 1H), 6.75 (d, $J = 8.3$ Hz, 1H), 7.12-7.17 (m, 3H), 7.28 (brs, 1H), 7.37 (t, $J = 8.6$ Hz, 1H), 7.59 (d, $J = 7.5$ Hz, 2H). ^{13}C NMR ($CDCl_3$) δ : 14.0, 18.7, 20.5, 31.3, 42.9, 111.9, 114.2, 114.4, 127.5, 127.7, 128.4, 133.4, 134.1, 135.7, 150.5, 168.6; HRMS (TOF-MS) calcd. for $C_{19}H_{25}N_2O$ ($M+H^+$): 297.1967; found 297.1969

2-(butylamino)-N-(2,6-diisopropylphenyl)benzamide (**4h**)




Following the general procedure above (Condition A), using **1h** (203.7 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **4h** (147.7 mg, 84%), Viscous colorless oil.; IR (neat) ν 3370, 3272, 2959, 2865, 1627, 1512, 1273, 1166, 742 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.95 (t, J = 7.3 Hz, 3H), 1.26 (d, J = 6.7 Hz, 12H), 1.46 (sext, J = 7.6 Hz, 2H), 1.65 (quint, J = 7.0 Hz, 2H), 3.15-3.22 (m, 4H), 6.69 (t, J = 7.3 Hz, 1H), 6.77 (d, J = 8.5 Hz, 1H), 7.25-7.27 (m, 3H), 7.36 (d, J = 7.6 Hz, 1H), 7.40 (t, J = 8.4 Hz, 1H), 7.56 (brs, 1H), 7.62 (d, J = 7.8 Hz, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.4, 23.7, 29.0, 31.3, 42.8, 111.9, 114.4, 114.6, 123.7, 127.5, 128.6, 131.2, 133.3, 146.6, 150.4, 169.7; HRMS (TOF-MS) calcd. for C₂₃H₃₃N₂O (M+H⁺): 353.2593; found 353.2594

2-(butylamino)-N-(2,6-dimethoxyphenyl)benzamide (**4i**)




Following the general procedure above (Condition A), using **1i** (191.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **4i** (163.8 mg, 99%), Viscous colorless oil.; IR (neat) ν 3336, 3261, 3068, 3023, 2965, 2923, 2836, 1636, 1581, 1509, 1475, 1254, 1114 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.92 (t, J = 7.4 Hz, 3H), 1.43 (sext, J = 7.4 Hz, 2H), 1.63 (quint, J = 7.5 Hz, 2H), 3.14 (q, J = 6.9 Hz, 2H), 3.83 (s, 6H), 6.61 (t, J = 7.2 Hz, 1H), 6.63 (d, J = 8.4 Hz, 2H), 6.71 (d, J = 8.4 Hz, 1H), 7.19 (t, J = 8.4 Hz, 2H), 7.33 (t, J = 7.1 Hz, 1H), 7.56 (brs, 1H), 7.65 (d, J = 7.6 Hz, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.6, 31.4, 42.9, 56.1, 104.5, 111.5, 114.2, 114.8, 114.9, 127.3, 128.7, 133.1, 150.4, 155.1, 168.6; HRMS (TOF-MS) calcd. for C₁₉H₂₅N₂O₃ (M+H⁺): 329.1865; found 329.1866

2-(butylamino)-N-(3,5-dimethoxyphenyl)benzamide (**4j**)




Following the general procedure above (Condition A), using **1j** (191.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **4j** (164.0 mg, 99%), Viscous colorless oil.; IR (neat) ν 3333, 2956, 2928, 2856, 1533, 1450, 1149, 1067, 812, 747, 675 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.95 (t, J = 7.5 Hz, 3H), 1.45 (sext, J = 7.5 Hz, 2H), 1.65 (quint, J = 7.0 Hz, 2H), 3.15 (t, J = 7.0 Hz, 2H), 3.80 (s, 6H), 6.27 (t, J = 2.3 Hz, 1H), 6.61 (t, J = 7.3 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 6.78 (d, J = 2.0 Hz, 2H), 7.31-7.35 (m, 1H), 7.36 (brs, 1H), 7.46 (dd, J = 1.4 and 7.9 Hz, 1H), 7.71 (brs, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.4, 42.9, 55.5, 96.9, 98.9, 112.0, 114.6, 115.0, 127.5, 133.4, 139.8, 150.2, 161.2, 168.3; HRMS (TOF-MS) calcd. for C₁₉H₂₅N₂O₃ (M+H⁺): 329.1865; found 329.1865

2-(butylamino)-N-(p-tolyl)benzamide (**4k**)




Following the general procedure above (Condition A), using **1k** (168.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **4k** (136.0 mg, 96%), Viscous colorless oil.; IR (neat) ν 3382, 3315, 2954, 2927, 2859, 1634, 1509, 1254 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.95 (t, J = 7.2 Hz, 3H), 1.45 (sext, J = 7.6 Hz, 2H), 1.65 (quint, J = 7.4 Hz, 2H), 2.34 (s, 3H), 3.16 (q, J = 7.0 Hz, 2H), 6.62 (t, J = 6.8 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 7.17 (d, J = 8.4 Hz, 2H), 7.33 (t, J = 7.0 Hz, 1H), 7.41 (d, J = 8.4 Hz, 3H), 7.47 (dd, J = 1.5 and 7.7 Hz, 1H), 7.67 (brs, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 21.0, 31.4, 42.9, 111.9, 114.6, 115.1, 121.0, 127.5, 129.7, 133.3, 134.2, 135.4, 150.2, 168.3; HRMS (TOF-MS) calcd. for C₁₉H₂₅N₂O (M+H⁺): 297.1967; found 297.1967

2-(butylamino)-N-(2-methoxyphenyl)benzamide (**4l**)




Following the general procedure above (Condition A), using **1l** (176.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (2.0 mL) at room temperature for 20 h, yielded the product **4l** (124.7 mg, 84%), Viscous colorless oil.; IR (neat) ν 3415, 3364, 2956, 2934, 2901, 2869, 2842, 1644, 1514, 1456, 1249, 1228, 744 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.96 (t, J = 7.4 Hz, 3H), 1.47 (sext, J = 7.6 Hz, 2H), 1.67 (quint, J = 7.4 Hz, 2H), 3.18 (q, J = 7.1 Hz, 2H), 3.91 (s, 3H), 6.64 (t, J = 7.1 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 6.92 (dd, J = 1.3 and 8.0 Hz, 1H), 7.01 (t, J = 7.7 Hz, 1H), 7.07 (dt, J = 1.6 and 7.8 Hz, 1H), 7.37 (t, J = 7.8 Hz, 1H), 7.52 (d, J = 7.9 Hz, 2H), 8.38 (d, J = 8.0 Hz, 1H), 8.41 (brs, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.4, 42.9, 55.9, 110.1, 111.8, 114.5, 115.4, 120.1, 121.2, 123.8, 127.7, 127.9, 133.2, 148.5, 150.3, 168.1; HRMS (TOF-MS) calcd. for C₁₈H₂₃N₂O₂ (M+H⁺): 299.1760; found 299.1758

2-(butylamino)-N-(3-methoxyphenyl)benzamide (**4m**)




Following the general procedure above (Condition A), using **1m** (176.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **4m** (128.2 mg, 86%), Viscous colorless oil.; IR (neat) ν 3393, 3271, 2916, 2856, 1633, 1576, 1490, 1414, 1281, 1156, 1045 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.97 (t, J = 7.4 Hz, 3H), 1.47 (sext, J = 7.4 Hz, 2H), 1.66 (quint, J = 7.1 Hz, 2H), 3.16 (t, J = 7.1 Hz, 2H), 3.83 (s, 3H), 6.61 (t, J = 7.1 Hz, 1H), 6.70-6.74 (m, 2H), 7.07 (d, J = 8.0 Hz, 1H), 7.24-7.29 (m, 2H), 7.32-7.36 (m, 1H), 7.40 (brs, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.83 (brs, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.4, 42.9, 55.4, 106.5, 110.3, 112.0, 113.0, 114.6, 115.0, 127.6, 129.8, 133.4, 139.3, 150.3, 160.3, 168.4; HRMS (TOF-MS) calcd. for C₁₈H₂₃N₂O₂ (M+H⁺): 299.1760; found 299.1761

2-(butylamino)-N-(4-methoxyphenyl)benzamide (**4n**)




Following the general procedure above (Condition A), using **1n** (176.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (2.0 mL) at room temperature for 20 h, yielded the product **4n** (147.9 mg, 99%), Viscous colorless oil.; IR (neat) ν 3385, 3271, 2958, 2915, 2854, 1632, 1508, 1229, 1029, 821 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.95 (t, J = 7.5 Hz, 3H), 1.45 (sext, J = 7.5 Hz, 2H), 1.65 (quint, J = 6.7 Hz, 2H), 3.15 (q, J = 6.9 Hz, 2H), 3.81 (s, 3H), 6.61 (t, J = 7.1 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 6.91 (d, J = 8.3 Hz, 2H), 7.33 (t, J = 8.0 Hz, 1H), 7.43 (d, J = 8.3 Hz, 3H), 7.47 (d, J = 7.7 Hz, 1H), 7.64 (brs, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.3, 43.1, 55.6, 112.1, 114.4, 114.8, 115.1, 122.9, 127.5, 130.9, 133.3, 150.0, 156.8, 168.3; HRMS (TOF-MS) calcd. for C₁₈H₂₃N₂O₂ (M+H⁺): 299.1760; found 299.1758

N-([1,1'-biphenyl]-2-yl)-2-(butylamino)benzamide (**4o**)




Following the general procedure above (Condition A), using **1o** (199.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (2.0 mL) at room temperature for 20 h, yielded the product **4o** (165.3 mg, 96%), Viscous colorless oil.; IR (neat) ν 3358, 3310, 2961, 2931, 2867, 2827, 1630, 1576, 1471, 698 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.80 (t, J = 7.4 Hz, 3H), 1.30 (sext, J = 7.7 Hz, 2H), 1.50 (quint, J = 7.5 Hz, 2H), 2.98 (t, J = 4.5 Hz, 2H), 6.26 (t, J = 7.2 Hz, 1H), 6.51 (d, J = 8.5 Hz, 1H), 6.81 (d, J = 7.8 Hz, 1H), 7.02-7.14 (m, 3H), 7.22-7.27 (m, 4H), 7.30-7.33 (m, 2H), 7.50 (brs, 1H), 7.70 (brs, 1H), 8.21 (d, J = 8.1 Hz, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.4, 42.9, 112.0, 114.5, 114.6, 121.8, 124.4, 127.2, 128.2, 128.6, 129.3, 129.5, 130.3, 132.9, 133.3, 135.2, 138.3, 150.6, 168.0; HRMS (TOF-MS) calcd. for C₂₃H₂₅N₂O (M+H⁺): 345.1967; found 345.1967

2-(butylamino)-N-(4-vinylphenyl)benzamide (**4p**)




Following the general procedure above (Condition A), using **1p** (174.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (2.0 mL) at room temperature for 20 h, yielded the product **4p** (118.5 mg, 81%), Viscous colorless oil.; IR (neat) ν 3392, 3263, 3094, 3035, 2955, 2924, 2858, 1636, 1576, 1508, 1298, 1245, 989 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.95 (t, J = 7.4 Hz, 3H), 1.46 (sext, J = 7.7 Hz, 2H), 1.65 (quint, J = 7.1 Hz, 2H), 3.16 (t, J = 7.1 Hz, 2H), 5.21 (d, J = 10.9 Hz, 1H), 5.71 (d, J = 17.6 Hz, 1H), 6.60-6.63 (m, 1H), 6.67-6.73 (m, 2H), 7.32-7.36 (m, 1H), 7.40-7.42 (m, 3H), 7.47 (dd, J = 1.5 and 7.9 Hz, 1H), 7.50-7.53 (m, 2H), 7.77 (brs, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.4, 42.9, 112.0, 113.2, 114.6, 114.8, 120.6, 127.0, 127.5, 133.4, 133.9, 136.3, 137.6, 150.3, 168.2; HRMS (TOF-MS) calcd. for C₁₉H₂₃N₂O (M+H⁺): 295.1810; found 295.1810

N-(3,5-bis(trifluoromethyl)phenyl)-2-(butylamino)benzamide (**4q**)




Following the general procedure above (Condition A), using **1q** (229.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **4q** (138.3 mg, 68%), Viscous colorless oil.; IR (neat) ν 3401, 3282, 2963, 1637, 1516, 1269, 1133 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.97 (t, J = 7.4 Hz, 3H), 1.47 (sext, J = 7.7 Hz, 2H), 1.68 (quint, J = 7.5 Hz, 2H), 3.18 (t, J = 7.1 Hz, 2H), 6.64 (t, J = 7.7 Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 7.37 (t, J = 7.5 Hz, 1H), 7.45 (brs, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.62 (s, 1H), 7.99 (brs, 1H), 8.08 (s, 2H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.3, 42.9, 112.5, 113.3, 114.8, 117.5 (m), 120.0 (d, J = 3.1 Hz), 123 (q, J = 273 Hz), 127.4, 132.5 (q, J = 33.2 Hz), 134.2, 139.7, 150.7, 168.2; HRMS (TOF-MS) calcd. for C₁₉H₁₉F₆N₂O (M+H⁺): 405.1402; found 405.1403

ethyl 4-(2-(butylamino)benzamido)benzoate (**4r**)




Following the general procedure above (Condition A), using **1r** (197.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **4r** (161.7 mg, 95%), Viscous colorless oil.; IR (neat) ν 3240, 3319, 2988, 2955, 2930, 2863, 1692, 1521, 1401, 1321, 1185, 854 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.95 (t, J = 7.4 Hz, 3H), 1.39 (t, J = 7.2 Hz, 3H), 1.45 (sext, J = 7.4 Hz, 2H), 1.65 (quint, J = 7.4 Hz, 2H), 3.16 (q, J = 6.9 Hz, 2H), 4.36 (q, J = 6.9 Hz, 2H), 6.60 (t, J = 7.2 Hz, 1H), 6.72 (d, J = 8.5 Hz, 1H), 7.32-7.35 (m, 1H), 7.42 (brs, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.65 (d, J = 8.7 Hz, 2H), 8.03 (d, J = 8.8 Hz, 3H). ¹³C NMR (CDCl₃) δ : 14.0, 14.5, 20.5, 31.3, 42.9, 61.0, 112.2, 114.3, 114.6, 119.4, 125.9, 127.6, 130.9, 133.8, 142.4, 150.5, 166.3, 168.3; HRMS (TOF-MS) calcd. for C₂₀H₂₅N₂O₃ (M+H⁺): 341.1865; found 341.1865

N-(4-acetylphenyl)-2-(butylamino)benzamide (**4s**)




Following the general procedure above (Condition A), using **1s** (182.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **4s** (117.5 mg, 76%), Viscous colorless oil.; IR (neat) ν 3384, 3352, 2959, 2933, 2853, 1671, 1645, 1509, 1340, 1254, 1154, 819 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.95 (t, J = 7.4 Hz, 3H), 1.46 (sext, J = 7.7 Hz, 2H), 1.66 (quint, J = 7.3 Hz, 2H), 2.58 (s, 3H), 3.17 (q, J = 6.9 Hz, 2H), 6.61 (t, J = 7.9 Hz, 1H), 6.73 (d, J = 8.5 Hz, 1H), 7.33-7.36 (m, 1H), 7.43 (brs, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.67 (d, J = 8.6 Hz, 2H), 7.96 (d, J = 8.6 Hz, 2H), 8.06 (s, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 26.6, 31.3, 42.9, 112.2, 114.2, 114.7, 119.6, 127.6, 129.9, 132.9, 133.8, 142.7, 150.5, 168.3, 197.2; HRMS (TOF-MS) calcd. for C₁₉H₂₃N₂O₂ (M+H⁺): 311.1760; found 311.1759

2-(butylamino)-N-(4-cyanophenyl)benzamide (**4t**)




Following the general procedure above (Condition B), using **1t** (174.1 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), K_3PO_4 (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **4t** (129.8 mg, 88%), Viscous colorless oil.; IR (neat) ν 3343, 2959, 2928, 2872, 2841, 2221, 1653, 1653, 1506, 1402, 1301, 1218, 835 cm^{-1} ; 1H NMR ($CDCl_3$) δ : 0.96 (t, $J = 7.6$ Hz, 3H), 1.46 (sext, $J = 7.6$ Hz, 2H), 1.66 (quint, $J = 7.3$ Hz, 2H), 3.17 (q, $J = 7.1$ Hz, 2H), 6.62 (t, $J = 7.2$ Hz, 1H), 6.74 (d, $J = 8.4$ Hz, 1H), 7.34-7.38 (m, 1H), 7.42 (brs, 1H), 7.49 (dd, $J = 1.5$ and 7.9 Hz, 1H), 7.60-7.62 (m, 2H), 7.68-7.71 (m, 2H), 8.04 (brs, 1H). ^{13}C NMR ($CDCl_3$) δ : 14.0, 20.5, 31.3, 42.9, 106.9, 112.3, 113.7, 114.7, 119.1, 120.2, 127.6, 133.4, 134.1, 142.4, 150.6, 168.3; HRMS (TOF-MS) calcd. for $C_{18}H_{20}N_3O$ ($M+H^+$): 294.1606; found 294.1607

2-(butylamino)-N-(4-nitrophenyl)benzamide (**4u**)




Following the general procedure above (Condition C), using **1u** (184.1 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Cs_2CO_3 (488.7 mg, 1.5 mmol, 3.0 equiv.) and Pyridine (1.0 mL) at room temperature for 20 h, yielded the product **4u** (133.4 mg, 85%), Viscous colorless oil.; IR (neat) ν 3428, 3396, 3314, 2955, 2926, 2853, 1660, 1491, 1298, 1209, 1109, 850 cm^{-1} ; 1H NMR ($CDCl_3$) δ : 0.95 (t, $J = 7.4$ Hz, 3H), 1.45 (sext, $J = 7.7$ Hz, 2H), 1.65 (quint, $J = 7.2$ Hz, 2H), 3.15 (q, $J = 6.9$ Hz, 2H), 6.59 (t, $J = 7.1$ Hz, 1H), 6.72 (d, $J = 8.6$ Hz, 1H), 7.34 (t, $J = 7.2$ Hz, 1H), 7.42 (brs, 1H), 7.49 (d, $J = 7.9$ Hz, 1H), 7.74 (d, $J = 9.2$ Hz, 3H), 8.17 (d, $J = 9.2$ Hz, 1H), 8.31 (brs, 1H). ^{13}C NMR ($CDCl_3$) δ : 13.9, 20.4, 31.3, 42.9, 112.3, 113.6, 114.7, 119.6, 125.1, 127.7, 134.2, 143.3, 144.4, 150.6, 168.3; HRMS (TOF-MS) calcd. for $C_{17}H_{20}N_3O_3$ ($M+H^+$): 314.1505; found 314.1506

2-(butylamino)-N-(2-iodophenyl)benzamide (**6a**)




Following the general procedure above (Condition C), using **5a** (224.5 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Pyridine (1.0 mL) at room temperature for 20 h, yielded the product **6a** (186.3 mg, 94%), Viscous colorless oil.; IR (neat) ν 3412, 3327, 2958, 2924, 2857, 1654, 1573, 1517, 1415, 1293, 1211, 1006, 732 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.97 (t, J = 7.4 Hz, 3H), 1.47 (sext, J = 7.5 Hz, 2H), 1.68 (quint, J = 7.3 Hz, 2H), 3.18 (q, J = 6.4 Hz, 2H), 6.65-6.68 (m, 1H), 6.75 (d, J = 8.7 Hz, 1H), 6.87 (dt, J = 1.6 and 7.4 Hz, 1H), 7.35-7.41 (m, 2H), 7.63-7.65 (m, 2H), 7.82 (dd, J = 1.4 and 8.0 Hz, 1H), 8.13 (brs, 1H), 8.29 (dd, J = 1.6 and 8.2 Hz, 1H). ¹³C NMR (CDCl₃) δ : 14.1, 20.5, 31.4, 42.9, 90.9, 112.1, 114.0, 114.7, 122.2, 126.0, 127.7, 129.3, 133.8, 138.5, 139.0, 150.7, 168.1; HRMS (TOF-MS) calcd. for C₁₇H₂₀IN₂O (M+H⁺): 395.0620; found 395.0620

2-(butylamino)-N-(3-iodophenyl)benzamide (**6b**)




Following the general procedure above (Condition A), using **5b** (224.5 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **6b** (170.1 mg, 86%), Viscous colorless oil.; IR (neat) ν 3384, 3269, 2597, 2920, 2854, 1636, 1577, 1512, 1410, 1273, 774 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.96 (t, J = 7.3 Hz, 3H), 1.45 (sext, J = 7.7 Hz, 2H), 1.66 (quint, J = 7.1 Hz, 2H), 3.16 (t, J = 7.0 Hz, 2H), 6.62 (t, J = 8.0 Hz, 1H), 6.73 (d, J = 8.4 Hz, 1H), 7.08 (t, J = 8.0 Hz, 1H), 7.35 (t, J = 8.5 Hz, 1H), 7.41 (brs, 1H), 7.44 (d, J = 7.9 Hz, 1H), 7.67 (d, J = 7.9 Hz, 1H), 7.50 (d, J = 8.2 Hz, 1H), 7.68 (brs, 1H), 7.98 (t, J = 1.8 Hz, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.4, 42.9, 94.3, 112.1, 114.3, 114.6, 119.8, 127.5, 129.3, 130.6, 133.4, 133.7, 139.3, 150.4, 168.2.; HRMS (TOF-MS) calcd. for C₁₇H₂₀IN₂O (M+H⁺): 395.0620; found 395.0621

2-(butylamino)-N-(4-iodophenyl)benzamide (**6c**)




Following the general procedure above (Condition A), using **5c** (2224.5 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **6c** (138.2 mg, 70%), Viscous colorless oil.; IR (neat) ν 3340, 3332, 2955, 2924, 2859, 1635, 1573, 1497, 1388, 1279, 1218, 1005, 814 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.95 (t, J = 7.4 Hz, 3H), 1.45 (sext, J = 7.6 Hz, 2H), 1.65 (quint, J = 7.6 Hz, 2H), 3.16 (t, J = 6.9 Hz, 2H), 6.62 (t, J = 7.3 Hz, 1H), 6.72 (d, J = 8.4 Hz, 1H), 7.32-7.36 (m, 3H), 7.40 (brs, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.66 (d, J = 8.8 Hz, 2H), 7.70 (brs, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.4, 42.9, 87.7, 112.1, 114.5, 114.6, 122.5, 127.5, 133.7, 137.9, 138.1, 150.4, 168.2.; HRMS (TOF-MS) calcd. for C₁₇H₂₀IN₂O (M+H⁺): 395.0620; found 395.0622

N-(4-bromophenyl)-2-(butylamino)benzamide (**6d**)




Following the general procedure above (Condition A), using **5d** (201.0 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **6d** (157.2 mg, 91%), Viscous colorless oil.; IR (neat) ν 3407, 3351, 2960, 2926, 2857, 1644, 1573, 1502, 1390, 1284, 1151, 1008, 818 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.95 (t, J = 7.3 Hz, 3H), 1.45 (sext, J = 7.7 Hz, 2H), 1.65 (quint, J = 7.5 Hz, 2H), 3.16 (t, J = 7.0 Hz, 2H), 6.62 (t, J = 7.2 Hz, 1H), 6.73 (d, J = 8.3 Hz, 1H), 7.34 (t, J = 8.6 Hz, 1H), 7.40 (brs, 1H), 7.43-7.49 (m, 5H), 7.71 (brs, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.4, 42.9, 112.2, 114.4, 114.7, 117.1, 122.2, 127.5, 132.2, 133.7, 137.2, 150.4, 168.2.; HRMS (TOF-MS) calcd. for C₁₇H₂₀BrN₂O (M+H⁺): 347.0759; found 347.0760

2-(butylamino)-N-(4-chlorophenyl)benzamide (**6e**)




Following the general procedure above (Condition A), using **5e** (178.8 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **6e** (125.3 mg, 83%), Viscous colorless oil.; IR (neat) ν 3395, 3331, 2958, 2928, 2858, 1637, 1574, 1501, 1394, 820 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.95 (t, *J* = 7.4 Hz, 3H), 1.45 (sext, *J* = 7.5 Hz, 2H), 1.66 (quint, *J* = 7.3 Hz, 2H), 3.16 (t, *J* = 6.9 Hz, 2H), 6.62 (t, *J* = 7.9 Hz, 1H), 6.73 (d, *J* = 8.5 Hz, 1H), 7.31-7.36 (m, 3H), 7.40 (brs, 1H), 7.46 (d, *J* = 7.9 Hz, 1H), 7.50 (d, *J* = 8.9 Hz, 2H), 7.71 (brs, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.4, 42.9, 112.1, 114.5, 114.6, 122.0, 127.5, 129.2, 129.5, 133.6, 136.6, 150.4, 168.3; HRMS (TOF-MS) calcd. for C₁₇H₂₀ClN₂O (M+H⁺): 303.1264; found 303.1266

2-(butylamino)-N-(4-fluorophenyl)benzamide (**6f**)



Following the general procedure above (Condition A), using **5f** (170.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **6f** (128.7 mg, 90%), Viscous colorless oil.; IR (neat) ν 3403, 3330, 2955, 2929, 2850, 1632, 1509, 1400, 1211, 1154, 818 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.95 (t, *J* = 7.4 Hz, 3H), 1.45 (sext, *J* = 7.6 Hz, 2H), 1.65 (quint, *J* = 7.7 Hz, 2H), 3.15 (t, *J* = 7.1 Hz, 2H), 6.61 (t, *J* = 8.2 Hz, 1H), 6.73 (d, *J* = 8.4 Hz, 1H), 7.05 (t, *J* = 8.6 Hz, 2H), 7.34 (t, *J* = 7.0 Hz, 1H), 7.43 (brs, 1H), 7.46-7.50 (m, 3H), 7.73 (brs, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.4, 42.9, 112.1, 114.6, 114.6, 115.8 (d, *J* = 22.0 Hz), 112.8 (d, *J* = 8.0 Hz), 127.5, 133.5, 133.9 (d, *J* = 2.8 Hz), 150.4, 159.7 (d, *J* = 243.7 Hz), 168.3.; HRMS (TOF-MS) calcd. for C₁₇H₂₀FN₂O (M+H⁺): 287.1560; found 287.1560


4-(2-(butylamino)benzamido)phenyl trifluoromethanesulfonate (**6g**)



Following the general procedure above (Condition A), using **5g** (235.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **6g** (195.9 mg, 94%), Viscous colorless oil.; IR (neat) ν 3417, 3351, 2968, 2930, 2846, 1646, 1508, 1423, 1219, 1194, 1134, 890 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.96 (t, *J* = 7.3 Hz, 3H), 1.46 (sext, *J* = 7.3


Hz, 2H), 1.66 (quint, $J = 7.8$ Hz, 2H), 3.16 (t, $J = 7.1$ Hz, 2H), 6.63 (t, $J = 7.4$ Hz, 1H), 6.74 (d, $J = 8.5$ Hz, 1H), 7.27 (d, $J = 8.5$ Hz, 2H), 7.63 (t, $J = 8.5$ Hz, 1H), 7.40 (brs, 1H), 7.46 (d, $J = 7.8$ Hz, 1H), 7.64 (d, $J = 9.0$ Hz, 2H), 7.83 (brs, 1H). ^{13}C NMR (CDCl_3) δ : 14.0, 20.5, 31.4, 42.9, 112.3, 114.1, 114.7, 118.9 (q, $J = 322.3$ Hz), 121.8, 122.2, 122.7, 127.5, 133.9, 138.2, 145.5, 150.5, 168.3.; HRMS (TOF-MS) calcd. for $\text{C}_{18}\text{H}_{20}\text{F}_3\text{N}_2\text{O}_4\text{S}$ ($\text{M}+\text{H}^+$): 417.1096; found 417.1097

2-(butylamino)-5-iodo-N-phenylbenzamide (**6h**)




Following the general procedure above (Condition C), using **5h** (224.5 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Cs_2CO_3 (488.7 mg, 1.5 mmol, 3.0 equiv.) and Pyridine (1.0 mL) at room temperature for 20 h, yielded the product **6h** (177.4 mg, 90%), Viscous colorless oil.; IR (neat) ν 3384, 3283, 2960, 2928, 2862, 1635, 1499, 1311, 1248, 750 cm^{-1} ; ^1H NMR (CDCl_3) δ : 0.94 (t, $J = 7.3$ Hz, 3H), 1.43 (sext, $J = 7.7$ Hz, 2H), 1.62 (quint, $J = 7.7$ Hz, 2H), 3.11 (t, $J = 6.5$ Hz, 2H), 6.49 (d, $J = 8.9$ Hz, 1H), 7.16 (t, $J = 7.6$ Hz, 1H), 7.35-7.38 (m, 3H), 7.52-7.54 (m, 3H), 7.67 (brs, 1H), 7.71 (d, $J = 2.1$ Hz, 1H). ^{13}C NMR (CDCl_3) δ : 14.0, 20.5, 31.2, 42.8, 74.0, 114.3, 117.5, 120.9, 124.9, 129.2, 135.7, 137.6, 141.5, 149.5, 167.0; HRMS (TOF-MS) calcd. for $\text{C}_{17}\text{H}_{20}\text{IN}_2\text{O}$ ($\text{M}+\text{H}^+$): 395.0620; found 395.0623

2-(butylamino)-3,5-diiodo-N-phenylbenzamide (**6i**)




Following the general procedure above (Condition B), using **5i** (287.5 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), K_3PO_4 (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **6i** (164.0 mg, 63%), Viscous colorless oil.; IR (neat) ν 3355, 3241, 3044, 2946, 2929, 2856, 1644, 1526, 1317, 1237, 269 cm^{-1} ; ^1H NMR (CDCl_3) δ : 0.88 (t, $J = 7.2$ Hz, 3H), 1.37 (sext, $J = 7.7$ Hz, 2H), 1.61 (quint, $J = 7.3$ Hz, 2H), 2.98 (t, $J = 7.2$ Hz, 2H), 7.14 (t, $J = 7.4$ Hz, 1H), 7.37 (t, $J = 7.5$ Hz, 2H), 7.66 (d, $J = 7.5$ Hz, 2H), 8.16 (d, $J = 2.2$ Hz, 1H), 8.32 (d, $J = 2.1$ Hz, 1H), 10.6 (brs, 1H). ^{13}C NMR (CDCl_3) δ : 13.9, 20.4, 32.6, 51.4, 87.3, 97.7, 120.0, 124.6, 129.0, 129.3, 138.1, 140.9, 146.8, 149.0, 162.6; HRMS (TOF-MS) calcd. for $\text{C}_{17}\text{H}_{19}\text{I}_2\text{N}_2\text{O}$ ($\text{M}+\text{H}^+$): 520.9587; found 520.9587

N-(2-bromophenyl)-2-(butylamino)benzamide (**6j**)




Following the general procedure above (Condition A), using **5j** (201.0 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **6j** (173.3 mg, 99%), Viscous colorless oil.; IR (neat) ν 3420, 3327, 2953, 2924, 2863, 1652, 1576, 1515, 1420, 1298, 1217, 1153, 1021, 733 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.97 (t, J = 7.4 Hz, 3H), 1.48 (sext, J = 7.4 Hz, 2H), 1.68 (quint, J = 7.2 Hz, 2H), 3.19 (q, J = 5.2 Hz, 2H), 6.68 (t, J = 7.2 Hz, 1H), 6.75 (d, J = 8.5 Hz, 1H), 7.0 (t, J = 8.0 Hz, 1H), 7.34-7.38 (m, 2H), 7.57-7.61 (m, 3H), 8.31 (brs, 1H), 8.4 (d, J = 8.3 Hz, 1H). ¹³C NMR (CDCl₃) δ : 14.1, 20.5, 31.4, 42.9, 112.1, 114.23, 114.24, 114.7, 112.1, 125.1, 127.6, 128.5, 132.4, 133.8, 136.1, 150.7, 168.0.; HRMS (TOF-MS) calcd. for C₁₇H₂₀BrN₂O (M+H⁺): 347.0759; found 347.0760

5-bromo-2-(butylamino)-N-phenylbenzamide (**6k**)




Following the general procedure above (Condition A), using **5k** (201.0 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **6k** (91.8 mg, 53%), Viscous colorless oil.; IR (neat) ν 3390, 3289, 2560, 2923, 2863, 1636, 1596, 1500, 1248, 808 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.94 (t, J = 7.4 Hz, 3H), 1.43 (sext, J = 7.7 Hz, 2H), 1.63 (quint, J = 7.0 Hz, 2H), 3.11 (q, J = 7.1 Hz, 2H), 6.60 (d, J = 9.0 Hz, 1H), 7.16 (t, J = 7.5 Hz, 1H), 7.35-7.41 (m, 4H), 7.53 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 2.4 Hz, 1H), 7.65 (brs, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.2, 43.0, 105.7, 113.7, 116.6, 120.9, 124.9, 129.2, 129.9, 135.9, 137.6, 149.1, 167.1.; HRMS (TOF-MS) calcd. for C₁₇H₂₀BrN₂O (M+H⁺): 347.0759; found 347.0761

N-(4-bromonaphthalen-1-yl)-2-(butylamino)benzamide (**6l**)




Following the general procedure above (Condition A), using **5l** (226.0 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), Pyridine Hydrochloride (2.9 mg, 0.025 mmol, 5.0 mol%), Cs₂CO₃ (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (0.5 mL) at room temperature for 20 h, yielded the product **6l** (181.9 mg, 92%), Viscous colorless oil.; IR (neat) ν 3393, 3203, 2954, 2924, 2857, 1627, 1515, 1498, 1250, 744 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.93 (t, *J* = 7.4 Hz, 3H), 1.43 (sext, *J* = 7.7 Hz, 2H), 1.65 (quint, 7.4 Hz, 2H), 3.13 (q, *J* = 7.1 Hz, 2H), 6.65 (t, *J* = 7.9 Hz, 1H), 6.75 (d, *J* = 8.4 Hz, 1H), 7.39 (t, *J* = 7.1 Hz, 1H), 7.50-7.53 (m, 2H), 7.58-7.64 (m, 3H), 7.73 (d, *J* = 8.0 Hz, 1H), 7.84 (d, *J* = 8.5 Hz, 1H), 8.14 (brs, 1H), 8.26 (d, *J* = 8.4 Hz, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.3, 42.9, 112.1, 114.0, 114.6, 120.3, 121.9, 122.5, 127.2, 127.5, 127.7, 128.1, 129.4, 129.7, 132.5, 132.6, 133.7, 150.6, 169.0.; HRMS (TOF-MS) calcd. for C₂₁H₂₂BrN₂O (M+H⁺): 397.0916; found 397.0917

2-(butylamino)-4-fluoro-N-phenylbenzamide (**6m**)




Following the general procedure above (Condition B), using **5m** (170.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), K₃PO₄ (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **6m** (140.4 mg, 98%), Viscous colorless oil.; IR (neat) ν 3385, 3322, 2962, 2929, 2855, 1638, 1582, 1513, 1437, 1176, 993, 742 cm⁻¹; ¹H NMR (CDCl₃) δ : 0.95 (t, *J* = 7.3 Hz, 3H), 1.44 (sext, *J* = 7.7 Hz, 2H), 1.64 (quint, *J* = 7.1 Hz, 2H), 3.10 (q, *J* = 5.1 Hz, 2H), 6.30 (dt, *J* = 2.6 and 8.6 Hz, 1H), 6.36 (dd, *J* = 2.4 and 12.3 Hz, 1H), 7.15 (t, *J* = 7.4 Hz, 1H), 7.37 (t, *J* = 7.5 Hz, 2H), 7.46 (dd, *J* = 6.2 and 8.7 Hz, 1H), 7.51 (d, *J* = 7.8 Hz, 2H), 7.62 (brs, 1H), 7.70 (brs, 1H). ¹³C NMR (CDCl₃) δ : 14.0, 20.5, 31.1, 43.0, 98.2 (d, *J* = 25.7 Hz), 101.7 (d, *J* = 23.0 Hz), 112.3 (d, *J* = 1.9 Hz), 120.9, 124.7, 129.2, 129.6 (d, *J* = 11.7 Hz), 137.8, 152.6 (d, *J* = 12.2 Hz), 166 (d, *J* = 249 Hz), 167.7. HRMS (TOF-MS) calcd. for C₁₇H₂₀FN₂O (M+H⁺): 287.1560; found 287.1560

2-(butylamino)-6-fluoro-N-phenylbenzamide (**6n**)




Following the general procedure above (Condition B), using **5n** (170.6 mg, 0.50 mmol), **2a** (0.25 mL, 2.5 mmol, 5.0 equiv.), K_3PO_4 (212.3 mg, 1.0 mmol, 2.0 equiv.), CsOAc (96.0 mg, 0.5 mmol, 1.0 equiv.) and Pyridine (0.5 mL) at 80°C for 24 h, yielded the product **6n** (130.9 mg, 91%), Viscous colorless oil.; IR (neat) ν 3387, 3299, 2955, 2929, 2867, 1640, 1539, 1460, 1320, 1254, 1143, 785 cm^{-1} ; 1H NMR ($CDCl_3$) δ : 0.96 (t, J = 7.4 Hz, 3H), 1.46 (sext, J = 7.7 Hz, 2H), 1.67 (quint, 7.2 Hz, 2H), 3.16 (q, J = 6.4 Hz, 2H), 6.33 (dd, J = 8.0 and 13.3 Hz, 1H), 6.49 (d, J = 8.6 Hz, 1H), 7.15 (t, J = 7.4 Hz, 1H), 7.20-7.24 (m, 1H), 7.37 (t, J = 7.6 Hz, 2H), 7.58 (d, J = 7.7 Hz, 2H), 8.13 (brs, 1H), 8.34 (d, J = 17.5 Hz, 1H). ^{13}C NMR ($CDCl_3$) δ : 14.0, 20.5, 31.2, 43.3, 101.4 (d, J = 27.0 Hz), 102.7 (d, J = 13.5 Hz), 107.8 (d, J = 1.9 Hz), 121.2, 124.8, 129.2, 133.2 (d, J = 13.7 Hz), 137.8, 152.5 (d, J = 5.6 Hz), 162.4 (d, J = 243.4 Hz), 165.1.; HRMS (TOF-MS) calcd. for $C_{17}H_{20}FN_2O$ ($M+H^+$): 287.1560; found 287.1563

Reaction with other aryl halides



Synthetic applications

Synthesis of Mebroqualone (**9**)



General procedure for the synthesis of **7**

Following the general procedure above (Condition C), using **5j** (201.0 mg, 0.50 mmol), Ammonia solution 7 N in methanol **2t** (3.0 mL), Cs_2CO_3 (488.7 mg, 1.5 mmol, 3.0 equiv.) and Dichloromethane (1.0 mL) at room temperature for 24 h, yielded the product **7** (136.9 mg, 94%); 1H NMR ($CDCl_3$) δ : 5.63 (brs, 2H), 6.73-6.76 (m, 2H), 7.01 (dt, $J = 1.7$ and 7.9 Hz, 1H), 7.28 (t, $J = 7.9$ Hz, 1H), 7.36 (t, $J = 8.4$ Hz, 1H), 7.57 (t, $J = 8.2$ Hz, 2H), 8.35 (brs, 1H), 8.44 (dd, $J = 1.5$ and 8.3 Hz, 1H). ^{13}C NMR ($CDCl_3$) δ : 114.2, 115.6, 117.1, 117.8, 122.1, 125.2, 127.3, 128.5, 132.4, 133.2, 136.0, 149.6, 167.4. Ref. Majumdar, K. C.; Ganai, S. *Synlett*. **2011**, 13, 1881-1887.


General procedure for the synthesis of **9**

An oven-dried 30 mL flask equipped with magnetic stir bar was charged with **7** (58.2 mg, 0.2 mmol, 1.0 equiv.), acetaldehyde (10 μ L, 0.24 mmol, 1.2 equiv.), I_2 (55.8 mg, 0.22 mmol, 1.1 equiv.), and EtOH (2 mL) were added. After cooling to room temperature, the reaction mixture was quenched with 5% $Na_2S_2O_3$ (1 mL) and concentrated to remove most of the solvent. The resulting residue was redissolved in ethyl acetate (15 mL), followed by the addition of brine (15 mL). The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (15 mL). The combined organic layer was dried over anhydrous $MgSO_4$, concentrated, and purified through silica gel column chromatography using a mixture of EtOAc and hexane as eluent to afford the **9** (43.7 mg, 70%). 1H NMR ($CDCl_3$) δ : 2.23 (s, 3H), 7.36 (dd, $J = 1.6$ and 7.8 Hz, 1H), 7.40 (dt, $J = 1.6$ and 7.8 Hz, 1H), 7.47-7.54 (m, 2H), 7.70 (d, $J = 7.7$ Hz, 1H), 7.79 (dt, $J = 1.4$ and 8.1 Hz, 2H), 8.29 (dd, $J = 1.3$ and 7.9 Hz, 1H). ^{13}C NMR ($CDCl_3$) δ : 23.8, 120.8, 123.0, 126.9, 127.0, 127.3, 129.2, 130.0, 131.1, 134.1, 134.9, 137.2, 147.6, 153.8, 161.6.


Ref. Kumar, D.; Jadhavar, P. S.; Nautiyal, M.; Sharma, H.; Meena, P. K.; Adane, L.; Pancholia, S.; Chakraborti, A. K. *RSC Adv.*, **2015**, 5, 30819-30825.

4. Spectral Charts for Products


¹H NMR (3a)




¹³C NMR (3a)




¹H NMR (3b)




¹³C NMR (3b)




¹H NMR (3c)




¹³C NMR (3c)




¹H NMR (3d)




¹³C NMR (3d)




¹H NMR (3e)




¹³C NMR (3e)




¹H NMR (3f)




¹³C NMR (3f)




¹H NMR (3g)




¹³C NMR (3g)




¹H NMR (3h)




¹³C NMR (3h)





¹H NMR (3i)





¹³C NMR (3i)




¹H NMR (3j)




¹³C NMR (3j)




¹H NMR (3k)




¹³C NMR (3k)




¹H NMR (31)




¹³C NMR (31)




¹H NMR (3m)




¹³C NMR (3m)




¹H NMR (3n)




NMR (3n)




¹H NMR (3q)




¹³C NMR (3q)




¹H NMR (3r)




¹³C NMR (3r)




¹H NMR (3s)




¹³C NMR (3s)




¹H NMR (3t)




¹³C NMR (3t)




^1H NMR (4b)




^{13}C NMR (4b)



¹H NMR (4c)




¹³C NMR (4c)




¹H NMR (4d)


B651-2 rs
single_pulse




¹³C NMR (4d)




¹H NMR (4e)




¹³C NMR (4e)





¹H NMR (4f)





¹³C NMR (4f)



¹H NMR (4g)




¹³C NMR (4g)





¹H NMR (4h)





¹³C NMR (4h)




¹H NMR (4i)




¹³C NMR (4i)




¹H NMR (4j)




¹³C NMR (4j)





¹H NMR (4k)





¹³C NMR (4k)




¹H NMR (41)




¹³C NMR (41)




¹H NMR (4m)




¹³C NMR (4m)






¹H NMR (4n)





¹³C NMR (4n)




¹H NMR (4o)




¹³C NMR (4o)




¹H NMR (4p)




¹³C NMR (4p)




¹H NMR (4q)




¹³C NMR (4q)




¹H NMR (4r)




¹³C NMR (**4r**)




¹H NMR (4s)




¹³C NMR (4s)




¹H NMR (4t)




¹³C NMR (4t)




¹H NMR (4u)




¹³C NMR (4u)




¹H NMR (6a)




¹³C NMR (6a)




¹H NMR (6b)




¹³C NMR (6b)




¹H NMR (6c)




¹³C NMR (6c)




¹H NMR (6d)




¹³C NMR (6d)




¹H NMR (6e)




¹³C NMR (6e)




¹H NMR (6f)




¹³C NMR (6f)




¹H NMR (6g)




¹³C NMR (6g)




¹H NMR (6h)




¹³C NMR (6h)




¹H NMR (6i)




¹³C NMR (6i)




¹H NMR (6j)




¹³C NMR (6j)




¹H NMR (6k)




¹³C NMR (6k)




¹H NMR (6l)




¹³C NMR (6l)




¹H NMR (6m)




¹³C NMR (6m)




¹H NMR (6n)




¹³C NMR (6n)




¹H NMR (7)



¹³C NMR (7)



¹H NMR (9)



¹³C NMR (9)

